Search research articles
Contact Us
Filters
Showing results (161-170 of 190) with videos related to
Page
of 19
Sort By:
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
June 17, 2022
Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder
Smadar V Tourjman, Gabriella Buck, Didier Jutras-Aswad, et al.
Translational Psychiatry
|
October 12, 2024
Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study
Benjamin Schwartzmann, Raaj Chatterjee, Yasaman Vaghei, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 30, 2020
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report
Katharine Dunlop, Sakina J Rizvi, Sidney H Kennedy, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
October 5, 2023
Influence of <i>CYP2C19</i>, <i>CYP2D6</i>, and <i>ABCB1</i> Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study
Farhana Islam, Leen Magarbeh, Samar S M Elsheikh, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
March 29, 2025
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l'aide des scores de risque polygéniques : Rapport sur l'étude CAN-BIND-1
Leen Magarbeh, Samar S M Elsheikh, Farhana Islam, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
October 15, 2019
Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report
Nikita Nogovitsyn, Meghan Muller, Roberto Souza, et al.
Biological Psychiatry Global Open Science
|
June 12, 2025
High Baseline Plasma Anthranilic Acid Predicts Remission Upon Acute-Series Ketamine Infusion for Treatment-Resistant Depression
Stephen A Murata, Zachary B Madaj, Colt D Capan, et al.
JAMA Psychiatry
|
February 11, 2026
One-Year Actigraphy Study of Sleep and Rest-Activity Rhythms as Markers of Relapse in Depression
Andre C Tonon, Adile Nexha, Jasmyn E A Cunningham, et al.
Psychoneuroendocrinology
|
July 6, 2021
Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report
Jee Su Suh, Laura M Fiori, Mohammad Ali, et al.
Pharmacopsychiatry
|
June 25, 2024
Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 Study
Farhana Islam, Amanda Lisoway, Edward S Oh, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 190) with videos related to
Sort By:
Page
of 19
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
June 17, 2022
Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder
Smadar V Tourjman, Gabriella Buck, Didier Jutras-Aswad, et al.
Translational Psychiatry
|
October 12, 2024
Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study
Benjamin Schwartzmann, Raaj Chatterjee, Yasaman Vaghei, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 30, 2020
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report
Katharine Dunlop, Sakina J Rizvi, Sidney H Kennedy, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
October 5, 2023
Influence of <i>CYP2C19</i>, <i>CYP2D6</i>, and <i>ABCB1</i> Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study
Farhana Islam, Leen Magarbeh, Samar S M Elsheikh, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
March 29, 2025
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l'aide des scores de risque polygéniques : Rapport sur l'étude CAN-BIND-1
Leen Magarbeh, Samar S M Elsheikh, Farhana Islam, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
October 15, 2019
Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report
Nikita Nogovitsyn, Meghan Muller, Roberto Souza, et al.
Biological Psychiatry Global Open Science
|
June 12, 2025
High Baseline Plasma Anthranilic Acid Predicts Remission Upon Acute-Series Ketamine Infusion for Treatment-Resistant Depression
Stephen A Murata, Zachary B Madaj, Colt D Capan, et al.
JAMA Psychiatry
|
February 11, 2026
One-Year Actigraphy Study of Sleep and Rest-Activity Rhythms as Markers of Relapse in Depression
Andre C Tonon, Adile Nexha, Jasmyn E A Cunningham, et al.
Psychoneuroendocrinology
|
July 6, 2021
Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report
Jee Su Suh, Laura M Fiori, Mohammad Ali, et al.
Pharmacopsychiatry
|
June 25, 2024
Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 Study
Farhana Islam, Amanda Lisoway, Edward S Oh, et al.
Page
of 19